首页|软骨肉瘤的表观遗传学研究进展

软骨肉瘤的表观遗传学研究进展

扫码查看
软骨肉瘤是第二常见的原发性恶性骨肿瘤,其治疗效果差,易复发和转移,对放化疗均不敏感,治疗方式在过去30~40年间停滞不前,还是以手术切除为主。对于软骨肉瘤的发生发展机制研究仍未完全明确,亦无特效药物。因此,探寻软骨肉瘤新的发生发展机制,从而寻找新的治疗方法和药物靶点,对临床治疗具有重大意义。有研究发现表观遗传学在软骨肉瘤发生发展中有重要作用。表观遗传学是指DNA序列未发生变化,但生物体的表型发生了可遗传性的改变,其机制主要包括DNA甲基化、非编码RNA调控、组蛋白修饰、染色质重塑等。该文就目前表观遗传学在软骨肉瘤中的研究进展做一综述,为进一步深入软骨肉瘤的研究,寻找新的治疗靶点提供方向。
Advances in Epigenetics of Chondrosarcoma
Chondrosarcoma(CHS)is the second most common primary bone malignancy in human.Recurrence and metasta-sis are common among patients,and the efficacies of radiotherapy and chemotherapy are limited.The development of CHS treat-ment method has stagnated in the past 30-40 years,and surgical treatment is still the dominant option.Research on the patho-genesis mechanism of CHS is still not clear,and there is no specific drug.Therefore,it is of great significance to explore the pathogenesis of CHS,so as to find new treatment methods and drug targets for clinical treatment.Some studies have shown that epigenetic factor play an important role in the pathogenesis of CHS.Epigenetics refers to changes in the expression level and function of a gene without the change in its DNA sequence,leading to a heritable phenotype.The mechanisms of epigenetics mainly include DNA methylation,non-coding RNA regulation,histone modification,and chromatin remodeling.In this review,the recent progress in the field of epigenetics in CHS is summarized,which provides a direction for further research on CHS and searching for new therapeutic targets.

chondrosarcomaepigeneticsDNA methylationnon-coding RNAhistone modification

李超、浦飞飞、刘建湘

展开 >

华中科技大学同济医学院附属协和医院骨科,武汉 430022

华中科技大学同济医学院附属武汉中西医结合医院骨科,武汉 430022

软骨肉瘤 表观遗传学 DNA甲基化 非编码RNA 组蛋白修饰

国家自然科学基金资助项目湖北省自然科学基金资助项目湖北省自然科学基金资助项目

820729782024AFB10112020CFB861

2024

华中科技大学学报(医学版)
华中科技大学

华中科技大学学报(医学版)

CSTPCD北大核心
影响因子:1.443
ISSN:1672-0741
年,卷(期):2024.53(3)